New York, New York, USA, November 16, 2026
Nuvation Bio Inc. has presented additional long-term clinical data from its Phase 2 study of safusidenib, an investigational targeted therapy for patients with IDH1-mutant glioma, at the 31st Annual Meeting of the Society for Neuro-Oncology (SNO) in Philadelphia, Pennsylvania. The updated findings from the J201 clinical study demonstrate sustained tumor responses and a manageable safety profile after extended treatment and follow-up. The research focused on patients with chemotherapy- and radiotherapy-naïve Grade 2 IDH1-mutant glioma, a type of brain tumor characterized by alterations in the isocitrate dehydrogenase 1 (IDH1) gene. With nearly 40 months of follow-up, the study reported a confirmed clinical benefit rate of 81.5%, alongside measurable reductions in tumor size. The findings provide additional evidence supporting the continued investigation of safusidenib as a potential targeted treatment for patients with IDH1-mutant brain tumors. Nuvation Bio is advancing the candidate through further clinical development, including a pivotal Phase 3 program intended to evaluate its therapeutic potential in additional treatment settings.
Phase 2 J201 Study Demonstrates Sustained Clinical Activity
The updated findings from the Phase 2 J201 study included 27 patients with Grade 2 IDH1-mutant glioma who had not previously received chemotherapy or radiotherapy. Safusidenib is an oral, brain-penetrant, selective inhibitor of mutant IDH1 designed to target the molecular abnormality associated with these tumors. Mutations in IDH1 can lead to the production of an abnormal metabolite called 2-hydroxyglutarate (2-HG), which contributes to changes in cellular processes involved in tumor development. By selectively inhibiting mutant IDH1, safusidenib is designed to reduce the production of this metabolite and potentially interfere with tumor-associated biological activity. In the updated analysis, the centrally assessed confirmed clinical benefit rate reached 81.5%, with a 95% confidence interval of 61.9% to 93.7%. The confirmed objective response rate was 51.9%, consisting of partial responses in 14.8% of patients and minor responses in 37.0%. Researchers also reported a median best reduction in target lesion size of 27.2%, indicating sustained tumor shrinkage among treated participants. The median time to response was 14.1 months, while the median duration of response had not been reached at the data cutoff. These findings suggest that responses may develop gradually and remain durable during continued treatment. The results are particularly relevant to research into lower-grade IDH1-mutant gliomas, where long-term disease management and treatment tolerability are important considerations.
Long-Term Follow-Up Shows Manageable Safety Profile
An important aspect of the updated research was the extended evaluation of treatment exposure and safety. The median duration of safusidenib exposure was 46.7 months, and the majority of patients remained on treatment for more than 36 months, with treatment continuing for several participants at the time of data cutoff. The company reported that the safety profile remained consistent with earlier clinical findings, with no new safety signals identified during longer follow-up. The most frequently reported treatment-emergent adverse events included alopecia (59.3%), arthralgia (55.6%), skin hyperpigmentation (51.9%), increased alanine aminotransferase (ALT) levels (40.7%), and rash (37.0%). Most reported events were low-grade and manageable through dose modifications. Treatment discontinuation due to adverse events occurred in 11.1% of participants, representing three patients. Earlier topline findings from the study had also reported a 36-month progression-free survival rate of 79% at a median follow-up of 38.8 months. Together, these results provide additional information about the potential durability of treatment responses and the longer-term tolerability of safusidenib. However, the study involved a relatively small patient population, and the findings require confirmation through larger clinical trials.
Nuvation Bio Advances Safusidenib Toward Phase 3 Development
Following the encouraging Phase 2 findings, Nuvation Bio is continuing the clinical development of safusidenib through its global clinical research program. The company is advancing the pivotal Phase 3 SIGMA study, which will evaluate safusidenib against placebo as maintenance therapy following standard-of-care treatment in patients with IDH1-mutant astrocytoma with high-risk features. The study is expected to enroll approximately 300 patients. Additional development includes the Phase 3 G307 study in regions where vorasidenib is not yet approved or accessible and the Phase 2 G209 study evaluating safusidenib in patients whose disease has progressed following vorasidenib treatment. In August 2026, the U.S. Food and Drug Administration granted Fast Track designation to safusidenib for IDH1-mutant glioma, supporting further development for this serious condition with significant unmet medical needs. The designation does not constitute marketing approval. The latest J201 findings strengthen the clinical evidence supporting continued evaluation of safusidenib, particularly its potential to provide sustained disease control in patients with IDH1-mutant glioma. Further results from ongoing clinical trials will be important in determining its efficacy, safety, and potential role in future treatment strategies.
Source: Nuvation Bio press release



